2019-001431-31: A Phase 2 Study Assessing the Safety and Efficacy of AT-527 in Combination with Daclatasvir in Subjects with Chronic HCV Infection |
|
|
| Not yet recruiting | 2 | 15 | Europe | Daklinza, AT-527, na, Tablet, Daklinza | Atea Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc. | HCV-Infected subjects, Hepatitis C, Diseases [C] - Virus Diseases [C02] | | | | |
